These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26605343)

  • 1. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
    Weber T; Mavratzas A; Kiesgen S; Haase S; Bötticher B; Exner E; Mier W; Grosse-Hovest L; Jäger D; Arndt MA; Krauss J
    J Immunol Res; 2015; 2015():561814. PubMed ID: 26605343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD22 Onconase: preparation and characterization.
    Newton DL; Stockwin LH; Rybak SM
    Methods Mol Biol; 2009; 525():425-43, xiv. PubMed ID: 19252847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
    Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
    Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
    Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-onconase conjugates: cytotoxicity and intracellular routing.
    Rybak SM
    Curr Pharm Biotechnol; 2008 Jun; 9(3):226-30. PubMed ID: 18673288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
    Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
    Newton DL; Hansen HJ; Mikulski SM; Goldenberg DM; Rybak SM
    Blood; 2001 Jan; 97(2):528-35. PubMed ID: 11154233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
    Sharkey RM; Govindan SV; Cardillo TM; Goldenberg DM
    Mol Cancer Ther; 2012 Jan; 11(1):224-34. PubMed ID: 22039078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
    Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
    Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.
    Catcott KC; McShea MA; Bialucha CU; Miller KL; Hicks SW; Saxena P; Gesner TG; Woldegiorgis M; Lewis ME; Bai C; Fleming MS; Ettenberg SA; Erickson HK; Yoder NC
    MAbs; 2016; 8(3):513-23. PubMed ID: 26752675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.
    Ziaei V; Ghassempour A; Davami F; Azarian B; Behdani M; Dabiri H; Habibi-Anbouhi M
    Mol Cell Biochem; 2024 Mar; 479(3):579-590. PubMed ID: 37129769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.
    Pfeifer M; Zheng B; Erdmann T; Koeppen H; McCord R; Grau M; Staiger A; Chai A; Sandmann T; Madle H; Dörken B; Chu YW; Chen AI; Lebovic D; Salles GA; Czuczman MS; Palanca-Wessels MC; Press OW; Advani R; Morschhauser F; Cheson BD; Lenz P; Ott G; Polson AG; Mundt KE; Lenz G
    Leukemia; 2015 Jul; 29(7):1578-86. PubMed ID: 25708834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
    Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
    Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.